For nearly three decades, IV dihydroergotamine (DHE) has been an option for treatment of refractory migraine in both emergency and inpatient settings. Nagy and colleagues (2011) examined a large ...

Refractory migraine: This type of migraine is a migraine that may improve with medication for a brief period but will recur when the drug wears off. Daily persistent headache: This headache type ...

Medically reviewed by Nicholas R. Metrus, MDMedically reviewed by Nicholas R. Metrus, MD Migralepsy is a migraine-triggered ...

A migraine episode may have up to four distinct stages or phases, each of varying duration: prodrome, aura, headache, and postdrome. But not everyone experiences all the stages all the time.

Figure 1: A personal view on how future studies of migraine and PFO should be conducted. Most patients with severe disabling and refractory migraine, including those with previous paradoxical ...

[30] ZNS was studied for migraine prevention in 2 open-label trials presented. The first evaluated 33 patients with mixed headache disorders and refractory migraines. [35] Most had not responded ...

Patients who are unresponsive to 4–8 weeks' treatment with PPIs twice daily might have so-called refractory GERD. The first investigation these patients should undergo is upper endoscopy to ...

if you have the condition known as chronic migraine, you get headaches 15 or more days a month for at least 3 months. These headaches happen more than 15 days each month for at least 3 months.

Emgality (galcanezumab-gnlm) is prescribed for migraine prevention and to treat cluster headaches. Emgality may cause mild side effects and serious side effects. Like all medications, Emgality can ...

Aug. 28, 2024 — When taken at the first signs of a migraine, before headache pain begins, a drug called ubrogepant may be effective in helping people with migraine go about their daily lives ...

GI bleeding disorders. Liver cirrhosis. Hepatic or renal impairment. Discontinue if signs/symptoms of GI bleed, migraine is not relieved or worsens after first dose, tinnitus, loss of hearing ...

In 2023 Cullgen completed a Series C financing led by AstraZeneca-CICC Venture Capital Partnership, and also announced a strategic partnership with Astellas Pharma Inc.